Evidence map›Paper›PMID 37668833›Full record

ArticleInternational journal of hematology2023

Real-world data on induction therapy in patients with transplant-ineligible newly diagnosed multiple myeloma: retrospective analysis of 598 cases from Kansai Myeloma Forum.

Yuji Shimura, Hirohiko Shibayama, Aya Nakaya, Ryosuke Yamamura, Kazunori Imada, Hitomi Kaneko, Hitoshi Hanamoto, Shin-Ichi Fuchida, Hirokazu Tanaka, Satoru Kosugi and 20 more

Abstract read
PubMed Publisher
In one paragraph

Article in International journal of hematology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Trial
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

30 authors.

Yuji ShimuraDivision of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kamigyo-ku, Kyoto, 602-8566, Japan. yshimura@koto.kpu-m.ac.jp.ORCID http://orcid.org/0000-0001-9309-7902
Hirohiko ShibayamaDepartment of Hematology and Oncology, Osaka University Graduate School of Medicine, Osaka, Japan.
Aya NakayaDivision of Hematology, First Department of Internal Medicine, Kansai Medical University Medical Center, Osaka, Japan.
Ryosuke YamamuraDepartment of Hematology, Osaka Saiseikai Nakatsu Hospital, Osaka, Japan.
Kazunori ImadaDepartment of Hematology, Japanese Red Cross Osaka Hospital, Osaka, Japan.
Hitomi KanekoDepartment of Hematology, Japanese Red Cross Osaka Hospital, Osaka, Japan.
Hitoshi HanamotoDepartment of Hematology, Kindai University Nara Hospital, Nara, Japan.
Shin-Ichi FuchidaDepartment of Hematology, Japan Community Health Care Organization Kyoto Kuramaguchi Medical Center, Kyoto, Japan.
Hirokazu TanakaDepartment of Hematology and Rheumatology, Faculty of Medicine, Kindai University, Osaka, Japan.
Satoru KosugiDepartment of Internal Medicine (Hematology), Toyonaka Municipal Hospital, Osaka, Japan.
Miki KiyotaDepartment of Hematology, Matsushita Memorial Hospital, Osaka, Japan.
Toshimitsu MatsuiDepartment of Hematology, Nishiwaki Municipal Hospital, Hyogo, Japan.
Junya KandaDepartment of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Masato IidaKawasaki Hospital Internal Medicine, Hyogo, Japan.
Mitsuhiro MatsudaDepartment of Hematology, PL General Hospital, Osaka, Japan.
Nobuhiko UoshimaDepartment of Hematology, Japanese Red Cross Kyoto Daini Hospital, Kyoto, Japan.
Masaru ShibanoDepartment of Hematology, Sakai City Medical Center, Osaka, Japan.
Takahiro KarasunoDepartment of Hematology, Rinku General Medical Center, Osaka, Japan.
Tsuneyoshi HamadaHematology Div. Int. Med., Kyoto-Katsura Hospital, Kyoto, Japan.
Kensuke OhtaHematology Ohta Clinic, Shinsaibashi, Osaka, Japan.
Tomoki ItoFirst Department of Internal Medicine, Kansai Medical University, Osaka, Japan.
Hideo YagiDepartment of Hematology and Oncology, Nara Prefecture General Medical Center, Nara, Japan.
Satoshi YoshiharaDepartment of Internal Medicine, Division of Hematology, Hyogo College of Medicine, Hyogo, Japan.
Chihiro ShimazakiDepartment of Hematology, Japan Community Health Care Organization Kyoto Kuramaguchi Medical Center, Kyoto, Japan.
Shosaku NomuraFirst Department of Internal Medicine, Kansai Medical University, Osaka, Japan.
Masayuki HinoDepartment of Hematology, Osaka City University Graduate School of Medicine, Osaka, Japan.
Akifumi Takaori-KondoDepartment of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Itaru MatsumuraDepartment of Hematology and Rheumatology, Faculty of Medicine, Kindai University, Osaka, Japan.
Yuzuru KanakuraDepartment of Hematology, Sumitomo Hospital, Osaka, Japan.
Junya KurodaDivision of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kamigyo-ku, Kyoto, 602-8566, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To investigate the real-world clinical outcomes and management of novel drug-containing therapies for newly diagnosed multiple myeloma (MM) patients, we retrospectively analyzed data on the first-line treatment for newly diagnosed transplant-ineligible MM patients from Kansai Myeloma Forum, a registry network in Japan. A total of 598 patients treated with novel drugs between March 2007 and February 2018 were analyzed. Regimens used were VD (n = 305), Rd (n = 103), VMP (n = 97), VCD (n = 71), and VRd (n = 22). Younger patients tended to receive VRd or VCD, whereas the regimen with the highest median patient age was Rd. More than three-quarters of patients in the Rd group received a reduced dose of lenalidomide. The Rd and VRd groups had a relatively high incidence of infection and skin complications, and the VMP group had the highest incidence of peripheral neuropathy. Overall response rate did not differ significantly between regimens. Multivariate analysis in all patients revealed several poor prognostic factors, such as poor performance status. Novel drug-containing regimens for newly diagnosed MM showed a durable response with manageable AEs in the real-world setting.

Indexed as

Multiple MyelomaAntineoplastic Combined Chemotherapy ProtocolsBortezomibDexamethasoneDisease-Free SurvivalHumansInduction ChemotherapyRetrospective StudiesBortezomibDexamethasoneImmunomodulatory drugsMultiple myelomaProteosome inhibitors

Identifiers

PMID37668833

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.